Targeting Mutated p53: Naivete and Enthusiasm to Attempt the Impossible

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The tumor suppressor gene TP53 is frequently mutated in human cancers, often resulting in oncogenic gain-of-function phenotypes.
• Mutated p53 contributes to cancer progression and poor patient outcomes, yet effective therapeutic strategies remain elusive.
• Targeting mutated p53 has been a long-standing challenge in cancer research for over three decades.

Purpose of the Study:

• To provide a historical perspective on the therapeutic targeting of mutated p53.
• To highlight advances and challenges in developing drugs against mutated p53.
• To advocate for a functional p53 pathway restoration approach in drug discovery.

Main Methods:

• Review of historical advances and challenges in targeting mutated p53.
• Focus on a functional p53 pathway restoration strategy for drug discovery.
• Exploration of insights for functionally bypassing TP53 mutations.

Main Results:

• Mutated p53 functions as an oncogene, driving cancer progression.
• A functional pathway restoration approach offers a unique strategy for therapeutic intervention.
• Persistence and hard work are essential for discovering solutions to complex problems like targeting mutant p53.

Conclusions:

• Mutant p53 is a critical therapeutic target in cancer, akin to mutated Ras proteins.
• A dedicated 'p53 initiative' is warranted to accelerate drug discovery and development.
• Functional bypass strategies hold promise for benefiting cancer patients.